Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Reaffirmed by Royal Bank of Canada
Royal Bank of Canada reiterated their outperform rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $77.00 price target on the biopharmaceutical company’s stock. Several other research analysts also recently weighed in on RARE. Stifel Nicolaus upped their price […]
29 Sep 03:16 · The Cerbat Gem